Effect of Qingre Huashi Tiaoshu Prescription on Intestinal Mucosal Barrier Function in Mice with Ulcerative Colitis
10.13422/j.cnki.syfjx.20222294
- VernacularTitle:清热化湿调枢方对溃疡性结肠炎小鼠肠道黏膜屏障功能的影响
- Author:
Xiaolan SU
1
;
Lin WANG
1
;
Tao ZHANG
1
;
Xiangli QING
1
;
Gezhi ZHANG
1
;
Mengxi YAO
1
;
Wei WEI
1
Author Information
1. Beijing Key Laboratory of Traditional Chinese Medicine （TCM） Diagnosis and Treatment of Functional Gastrointestinal Diseases （BZ0374），Wangjing Hospital， Chinese Academy of Chinese Medical Sciences，Beijing 100102，China
- Publication Type:Journal Article
- Keywords:
Qingre Huashi Tiaoshu prescription;
mice with ulcerative colitis;
intestinal mucosal barrier;
mechanism of action
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2022;28(22):68-75
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the effect of Qingre Huashi Tiaoshu prescription on mice with ulcerative colitis （UC） based on the change of the intestinal mucosal barrier function. MethodSix of thirty-six C57BL/6 mice were randomly selected as the normal group. The remaining mice were free to drink 2.5% dextran sulfate sodium （DSS） solution for 7 days to prepare UC model mice. After modeling， they were randomly divided into model group， mesalazine group， and Qingre Huashi Tiaoshu prescription high-， medium- and low-dose groups， 6 in each group. Mesalazine group was given 0.52 g·kg-1·d-1 suspension （ig）. Qingre Huashi Tiaoshu prescription high-， medium- and low-dose groups were given 3.38， 1.69， 0.845 g·kg-1·d-1 suspension， respectively （ig）. The normal group and the model group were treated with an equal volume of purified water for 10 days （ig）. After intervention， the general condition， body weight， disease activity index （DAI） score， and colon length of the 6 groups of mice were compared. The colon tissue was stained with hematoxylin and eosin （HE） for pathological analysis， and the expression of Ki67 in colon tissue was detected by immunohistochemistry. Western blot was used to determine the protein expression of matrix metalloproteinase-9 （MMP-9）， cleaved cysteine aspartate-specific protease-3 （Caspase-3） and Caspase-3 in colon tissue. ResultCompared with the model group， the mesalazine group and the Qingre Huashi Tiaoshu prescription high- and medium-dose groups alleviated the diarrhea， blood in the stool， weight loss， and other symptoms in UC mice， reduced the DAI score （P<0.05）， and restored the colon shape （P<0.05）. The colonic mucosal defect and inflammatory cell infiltration were improved in the mesalazine group and the Qingre Huashi Tiaoshu prescription high- and medium-dose groups，and there were more intact crypt stem cells. Western blot showed that the protein expression of MMP-9 and cleaved Caspase-3 in the mesalazine group and the Qingre Huashi Tiaoshu prescription high-dose group was lower than that in the model group （P<0.05）， and there was no significant difference between the groups. The expression of Caspase-3 in the Qingre Huashi Tiaoshu high-dose prescription group was decreased compared with the condition in the model group （P<0.05）. ConclusionQingre Huashi Tiaoshu prescription could effectively relieve DSS-induced UC， and its mechanism of action might be related to regulating the expression of MMP-9， cleaved Caspase-3， and Caspase-3， and promoting the repair of intestinal mucosal barrier.
